SOLIGENIX, INC. Payments of Debt Issuance Costs
SOLIGENIX, INC. (SNGX) reported Payments of Debt Issuance Costs of $45.51 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2023-03-31
- SOLIGENIX, INC. payments of debt issuance costs for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- SOLIGENIX, INC. payments of debt issuance costs for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- SOLIGENIX, INC. payments of debt issuance costs for the quarter ending 2021-06-30 was -$446.93K, a 266.38% decline year-over-year.
- SOLIGENIX, INC. payments of debt issuance costs for the quarter ending 2021-03-31 was $492.44K, a 213.08% increase year-over-year.
- SOLIGENIX, INC. payments of debt issuance costs for fiscal 2021 was $45.51K, a 93.06% decline from fiscal 2020.
- SOLIGENIX, INC. payments of debt issuance costs for fiscal 2020 was $656.26K, a 396.87% increase from fiscal 2019.
- SOLIGENIX, INC. payments of debt issuance costs for fiscal 2019 was $132.08K.
- SOLIGENIX, INC. payments of debt issuance costs for fiscal 2017 was $164.82K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 6 month as first filed | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 9 month as first filed | Payments of Debt Issuance Costs 12 month | Payments of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | -$446.93K derived: sum of 3 quarters · filed 2023-03-31 | $45.51K 10-K · filed 2023-03-31 | $621.90K 10-K · filed 2022-03-29 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$446.93K derived: sum of 2 quarters · filed 2022-11-10 | $45.51K 10-Q · filed 2022-11-10 | $584.33K 10-Q · filed 2021-11-12 | $150.02K derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$446.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $45.51K 10-Q · filed 2022-08-12 | $496.45K 10-Q · filed 2021-08-13 | $150.02K derived: sum of 3 quarters · filed 2022-08-12 | $275.86K derived: sum of 4 quarters · filed 2022-08-12 | ||
| 2021-03-31 | $492.44K 10-Q · filed 2022-05-13 | $596.95K derived: sum of 2 quarters · filed 2022-05-13 | $722.79K derived: sum of 3 quarters · filed 2022-05-13 | $991.42K derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $104.51K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $230.35K derived: sum of 2 quarters · filed 2022-03-29 | $498.97K derived: sum of 3 quarters · filed 2022-03-29 | $656.26K 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $125.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $394.46K derived: sum of 2 quarters · filed 2021-11-12 | $551.75K 10-Q · filed 2021-11-12 | $581.67K derived: sum of 4 quarters · filed 2021-11-12 | |||
| 2020-06-30 | $268.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $425.92K 10-Q · filed 2021-08-13 | $455.83K derived: sum of 3 quarters · filed 2021-08-13 | $528.70K derived: sum of 4 quarters · filed 2021-08-13 | |||
| 2020-03-31 | $157.29K 10-Q · filed 2021-05-18 | $187.20K derived: sum of 2 quarters · filed 2021-05-18 | $260.08K derived: sum of 3 quarters · filed 2021-05-18 | $273.64K derived: sum of 4 quarters · filed 2021-05-18 | |||
| 2019-12-31 | $29.91K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $102.79K derived: sum of 2 quarters · filed 2021-03-30 | $116.35K derived: sum of 3 quarters · filed 2021-03-30 | $132.08K 10-K · filed 2021-03-30 | |||
| 2019-09-30 | $72.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $86.44K derived: sum of 2 quarters · filed 2020-11-12 | $102.17K 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | $13.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $29.29K 10-Q · filed 2020-08-14 | |||||
| 2019-03-31 | $15.73K 10-Q · filed 2020-05-15 | ||||||
| 2017-12-31 | $17.95K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $164.82K 10-K · filed 2019-03-26 | |||||
| 2017-09-30 | $146.88K 10-Q · filed 2017-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |